These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 11479225

  • 1. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Aug 01; 61(15):5850-6. PubMed ID: 11479225
    [Abstract] [Full Text] [Related]

  • 2. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
    Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Liénard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D.
    Cancer Res; 2001 Jan 15; 61(2):509-12. PubMed ID: 11212242
    [Abstract] [Full Text] [Related]

  • 3. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

  • 4. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.
    Cancer Res; 2003 Sep 01; 63(17):5601-6. PubMed ID: 14500401
    [Abstract] [Full Text] [Related]

  • 5. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr 01; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 6. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 2000 Aug 15; 60(16):4499-506. PubMed ID: 10969798
    [Abstract] [Full Text] [Related]

  • 7. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T, Tanaka F, Mori M, Takesako K, Sugimachi K, Akiyoshi T.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [Abstract] [Full Text] [Related]

  • 8. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A.
    J Immunol; 1999 Jun 01; 162(11):6849-54. PubMed ID: 10352307
    [Abstract] [Full Text] [Related]

  • 9. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 1999 May 01; 59(9):2167-73. PubMed ID: 10232604
    [Abstract] [Full Text] [Related]

  • 10. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ, Martin D, Elder E, Storkus WJ, Lotze MT.
    Clin Cancer Res; 1996 Jan 01; 2(1):87-95. PubMed ID: 9816095
    [Abstract] [Full Text] [Related]

  • 11. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T.
    Clin Cancer Res; 1999 Aug 01; 5(8):2236-41. PubMed ID: 10473111
    [Abstract] [Full Text] [Related]

  • 12. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Anticancer Res; 2009 Feb 01; 29(2):647-55. PubMed ID: 19331215
    [Abstract] [Full Text] [Related]

  • 13. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T.
    Eur J Immunol; 1994 Dec 01; 24(12):3038-43. PubMed ID: 7805731
    [Abstract] [Full Text] [Related]

  • 14. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J, Leng X, Peng J, Mou D, Pang X, Shang X, Chen W.
    Chin Med J (Engl); 2002 Jul 01; 115(7):1002-5. PubMed ID: 12150730
    [Abstract] [Full Text] [Related]

  • 15. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
    Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P.
    Cancer Res; 2000 Nov 15; 60(22):6272-5. PubMed ID: 11103782
    [Abstract] [Full Text] [Related]

  • 16. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H, Song Y, Hoon DS, Appella E, Celis E.
    Cancer Res; 2001 Jun 15; 61(12):4773-8. PubMed ID: 11406551
    [Abstract] [Full Text] [Related]

  • 17. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD.
    J Immunol; 1999 Feb 15; 162(4):2227-34. PubMed ID: 9973498
    [Abstract] [Full Text] [Related]

  • 18. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.
    Dietrich PY, Walker PR, Quiquerez AL, Perrin G, Dutoit V, Liénard D, Guillaume P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Mar 01; 61(5):2047-54. PubMed ID: 11280765
    [Abstract] [Full Text] [Related]

  • 19. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Dec 15; 161(12):6956-62. PubMed ID: 9862730
    [Abstract] [Full Text] [Related]

  • 20. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY.
    Cancer Lett; 2004 Aug 10; 211(2):219-25. PubMed ID: 15219945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.